Revaprazan

Overview

Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori -induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori -infected gastric inflammation and gastric ulcer.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > COX | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > ERK | Products > Signaling Pathways > Akt | Products > Signaling Pathways > Proton Pump

Product Information

• Catalog No.: HY-121851
• CAS No.: 199463-33-7
• Molecular Formula: C22H23FN4
• Molecular Weight: 362.44
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source